New studies have shown that in tumor cells, activation of CD73 can promote the adhesion of tumor cells through the EGFR pathway, produce B-cell lymphoma-2 (Bcl-2) and Bcl-xL to inhibit cell apoptosis, release matrix metalloproteinases (MMPs) to hydrolyze the ECM, and promote the remote migration of tumor cells [121]. Here, BCL2L1 is linked to neoplasm.